Despite risks of complication and suboptimal diagnostic yield, endomyocardial biopsy (EMB), an invasive procedure in which a piece of heart tissue is extracted and analyzed, remains the gold standard for diagnosing unexplained myocardial disease. Currently, EMB is performed by randomly sampling myocardial tissue. This tissue is then examined under a microscope for diagnosis. The diagnostic yield of the procedure is low because a relatively small area of the heart is sampled. Alternatively, increasing the number of samples increases cardiac scarring, which is also undesirable. This technology describes a non-invasive method of imaging over large areas of the heart that can be used to provide more information than EMB alone. This technology could be used by research laboratories and academic institutions to improve the detection of heart transplant rejection and cardiomyopathies, as well as provide information regarding the outcomes of treatment decisions and new therapy options.
由于技术保密工作限制,技术信息无法完全展现,请通过邮箱或短信联系我们,获取更多技术资料。
decrease sampling error
optical coherence tomography
earlier treatment interventions
increase diagnostic sensitivity
suboptimal diagnostic yield